Literature DB >> 20864677

Toll-like receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia are critical to viral control during herpes simplex virus 1 infection.

Graciela Kunrath Lima1, Guilherme Pimenta Zolini, Daniel Santos Mansur, Bráulio Henrique Freire Lima, Uschi Wischhoff, Ruiz Gerhardt Astigarraga, Marcela França Dias, Mariana das Graças Almeida Silva, Samantha Ribeiro Béla, Lis Ribeiro do Valle Antonelli, Rosa Maria Arantes, Ricardo Tostes Gazzinelli, André Báfica, Erna Geessien Kroon, Marco Antônio Campos.   

Abstract

Herpes simplex virus 1 (HSV-1) is a neurotropic DNA virus that is responsible for several clinical manifestations in humans, including encephalitis. HSV-1 triggers toll-like receptors (TLRs), which elicit cytokine production. Viral multiplication and cytokine expression in C57BL/6 wild-type (WT) mice infected with HSV-1 were evaluated. Virus was found in the trigeminal ganglia (TG), but not in the brains of animals without signs of encephalitis, between 2 and 6 days postinfection (d.p.i.). Cytokine expression in the TG peaked at 5 d.p.i. TLR9-/- and TLR2/9-/- mice were more susceptible to the virus, with 60% and 100% mortality, respectively, as opposed to 10% in the WT and TLR2-/- mice. Increased levels of both CXCL10/IP-10 and CCL2/MCP-1, as well as reduced levels of interferon-γ and interleukin 1-β transcripts, measured in both the TG and brains at 5 d.p.i., and the presence of virus in the brain were correlated with total mortality in TLR2/9-/- mice. Cytokine alterations in TLR2/9-/- mice coincided with histopathological changes in their brains, which did not occur in WT and TLR2-/- mice and occurred only slightly in TLR9-/- mouse brain. Increased cellularity, macrophages, CD8 T cells producing interferon-γ, and expression levels of TLR2 and TLR9 were detected in the TG of WT-infected mice. We hypothesize that HSV-1 infection is controlled by TLR-dependent immune responses in the TG, which prevent HSV-1 encephalitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864677      PMCID: PMC2966801          DOI: 10.2353/ajpath.2010.100121

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.

Authors:  O Takeuchi; K Hoshino; T Kawai; H Sanjo; H Takada; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

3.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.

Authors:  F Hayashi; K D Smith; A Ozinsky; T R Hawn; E C Yi; D R Goodlett; J K Eng; S Akira; D M Underhill; A Aderem
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

4.  A TLR2 ligand suppresses inflammation by modulation of chemokine receptors and redirection of leukocyte migration.

Authors:  Clive S McKimmie; Mark Moore; Alasdair R Fraser; Thomas Jamieson; Damo Xu; Claire Burt; Nick I Pitman; Robert J Nibbs; Iain B McInnes; Foo Y Liew; Gerard J Graham
Journal:  Blood       Date:  2009-02-06       Impact factor: 22.113

5.  Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide.

Authors:  E Lien; T K Means; H Heine; A Yoshimura; S Kusumoto; K Fukase; M J Fenton; M Oikawa; N Qureshi; B Monks; R W Finberg; R R Ingalls; D T Golenbock
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon.

Authors:  Christophe Préhaud; Françoise Mégret; Mireille Lafage; Monique Lafon
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite.

Authors:  M A Campos; I C Almeida; O Takeuchi; S Akira; E P Valente; D O Procópio; L R Travassos; J A Smith; D T Golenbock; R T Gazzinelli
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

8.  Detection of herpesvirus DNA by the polymerase chain reaction (PCR) in vitreous samples from patients with necrotising retinitis.

Authors:  M L Nogueira; R C Siqueira; N Freitas; J B Amorim; C A Bonjardim; P C Ferreira; F Oréfice; E G Kroon
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

9.  Interleukin-1beta promotes repair of the CNS.

Authors:  J L Mason; K Suzuki; D D Chaplin; G K Matsushima
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

10.  MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA.

Authors:  Dongxu Sun; Aihao Ding
Journal:  Nat Immunol       Date:  2006-02-19       Impact factor: 25.606

View more
  39 in total

1.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

2.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Differential Involvement during Latent Herpes Simplex Virus 1 Infection of the Superior and Inferior Divisions of the Vestibular Ganglia: Implications for Vestibular Neuritis.

Authors:  Susanne Himmelein; Anja Lindemann; Inga Sinicina; Anja K E Horn; Thomas Brandt; Michael Strupp; Katharina Hüfner
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised.

Authors:  Ik L Tan; Justin C McArthur; Arun Venkatesan; Avindra Nath
Journal:  Neurology       Date:  2012-11-07       Impact factor: 9.910

5.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

Review 6.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

7.  TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS.

Authors:  Niranjan B Butchi; Tyson Woods; Min Du; Timothy W Morgan; Karin E Peterson
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

Review 8.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

9.  Herpes simplex virus US3 tegument protein inhibits Toll-like receptor 2 signaling at or before TRAF6 ubiquitination.

Authors:  Jayita Sen; Xueqiao Liu; Richard Roller; David M Knipe
Journal:  Virology       Date:  2013-03-07       Impact factor: 3.616

10.  Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection.

Authors:  Rafik Menasria; Nicolas Boivin; Manon Lebel; Jocelyne Piret; Jean Gosselin; Guy Boivin
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.